Skip to content

Pharminent

cropped-ChatGPT-Image-May-28-2026-10_46_23-PM.png
Primary Menu
  • Home
  • Signal News
  • Biopharma Brief
    • Market Access Intelligence
    • Rare Disease Gene Therapy
    • Oncology
  • Week in Review
    • GLP-1 Competitive Market
    • NeuroMarket Pulse
      • Neurology Regulatory Interactive Calendar
    • Manufacturing Intelligence
  • Contact
Light/Dark Button
Brief
  • Home
  • Regulatory
  • GSK again pulls application for leucovorin, touted by FDA as potential autism treatment
  • Regulatory

GSK again pulls application for leucovorin, touted by FDA as potential autism treatment

BioSpace

GSK discontinued Wellcovorin in 1999, but the FDA in September last year asked the pharma to refile an application, pointing to its potential to...

RegulatoryNeuroscienceRead full story

pharminent April 10, 2026 (Last updated: April 10, 2026)

BioSpace

GSK discontinued Wellcovorin in 1999, but the FDA in September last year asked the pharma to refile an application, pointing to its potential to…

RegulatoryNeuroscienceRead full story

Sign up to receive free daily digest

Check your inbox or spam folder to confirm your subscription.

Post navigation

Previous: Roche places a $1bn bet on C4T degrader-antibody conjugates
Next: Senju launches first-in-class dry eye disease drug in Japan

Related Stories

  • Regulatory

FDA Issues Draft Guidance to Help Accelerate Cell and Gene Therapies for Patients

pharminent June 2, 2026
  • Regulatory

FDA approves AstraZeneca’s Imfinzi-BCG combination for NMIBC therapy

pharminent June 1, 2026
  • Regulatory

Replimune gives cancer immunotherapy a third try after FDA leadership shakeup

pharminent May 29, 2026

You May Have Missed

  • Policy / Pricing

Eli Lilly issues data sharing ultimatum to 340B hospitals

pharminent June 2, 2026
  • M&A / Deals

Fulcrum exploring a potential sale after FDA sidelined its sickle cell drug

pharminent June 2, 2026
  • Clinical Data

ASCO 2026: Kelonia presents positive in vivo CAR-T data in multiple myeloma

pharminent June 2, 2026
  • Clinical Data

ASCO26: In vivo oncology approaches continue to show promise

pharminent June 2, 2026
Copyright © 2026 All rights reserved. | ReviewNews by AF themes.